ArticleBritish journal of pharmacology2005
Evolving the concept of regulation of vascular tone in humans.
Article in British journal of pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elucidation of mechanisms regulating microcirculatory vascular tone is a key issue in the knowledge of human pathophysiology. Anandamide is an endogenous lipidic cannabinoid (CB) characterized by potent vasodilator activity acting mainly through the activation of CB receptors, located on the vessel walls, and the vanilloid receptor 1, located on sensory peptidergic nerve endings within the external layers of vessel walls. In humans, cutaneous anandamide administration causes forearm skin vasodilation by activating vanilloid receptor 1 presumably on primary sensory nerves, while intrabrachial infusion of the same compound is devoid of effect on forearm muscle microcirculation. Taken together, these results indicate that, apart from a possible distrectual difference, the effect of anandamide is specific for the abluminal, but not for the endoluminal, part of the vessel wall. Thus, it is conceivable that, at least in the peripheral microcirculation, this compound could act as an autocrine/paracrine agent and not as a circulating hormone. In line with this possibility, it has been demonstrated that anandamide can be produced by macrophages and therefore its biological effect might increase in clinical conditions characterized by augmented activity of this cell line, including cardiogenic, hemorrhagic and endotoxic shock and even in atherosclerosis, inflammation and ischemia. Moreover, increased serum values of anandamide have been found in patients with endotoxic shock. However, decisive information concerning the role of anandamide in humans will be obtained when specific antagonists or inhibitors will be available. In that case, the anandamide system might represent a potential target for the treatment of important cardiovascular conditions, including severe shock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.